ES2636944T3 - Aislamiento, identificación y caracterización de cepas con actividad probiótica a partir de heces de lactantes alimentados exclusivamente con leche materna - Google Patents

Aislamiento, identificación y caracterización de cepas con actividad probiótica a partir de heces de lactantes alimentados exclusivamente con leche materna Download PDF

Info

Publication number
ES2636944T3
ES2636944T3 ES14190648.7T ES14190648T ES2636944T3 ES 2636944 T3 ES2636944 T3 ES 2636944T3 ES 14190648 T ES14190648 T ES 14190648T ES 2636944 T3 ES2636944 T3 ES 2636944T3
Authority
ES
Spain
Prior art keywords
feces
breast milk
strains
characterization
isolation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14190648.7T
Other languages
English (en)
Inventor
José María VIEITES FERNÁNDEZ
Sergio MUÑOZ QUEZADA
Inmaculada Llamas Company
José MALDONADO LOZANO
Fernando Romero Braquehais
Antonio Francisco SUÁREZ GARCÍA
Ángel GIL HERNÁNDEZ
Carolina GÓMEZ LLORENTE
Miriam BERMÚDEZ BRITO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hero AG
Original Assignee
Hero AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hero AG filed Critical Hero AG
Application granted granted Critical
Publication of ES2636944T3 publication Critical patent/ES2636944T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/175—Rhamnosus
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/51—Bifidobacterium
    • A23V2400/519—Breve
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pediatric Medicine (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)

Abstract

Una cepa de microorganismo probiotico aislada de heces de ninos alimentados exclusivamente con leche materna caracterizada porque consiste en Bifidobacterium breve HERO 15B con numero de referencia CNCM I-4035, depositada el 2 de julio de 2008 en el CNCM National Collection of Microorganism Culture, Pasteur Institute 25, Rue du Docteur Roux, F-75724 Paris.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21
imagen22
imagen23
imagen24
imagen25
imagen26
imagen27
imagen28
imagen29
imagen30
imagen31

Claims (1)

  1. imagen1
    imagen2
ES14190648.7T 2009-03-10 2010-03-09 Aislamiento, identificación y caracterización de cepas con actividad probiótica a partir de heces de lactantes alimentados exclusivamente con leche materna Active ES2636944T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
WOPCT/ES2009/000130 2009-03-10
PCT/ES2009/000130 WO2010103132A1 (es) 2009-03-10 2009-03-10 Aislamiento, identificación y caracterización de cepas con actividad probiótica a partir de heces de lactantes alimentados exclusivamente con leche materna

Publications (1)

Publication Number Publication Date
ES2636944T3 true ES2636944T3 (es) 2017-10-10

Family

ID=42727821

Family Applications (3)

Application Number Title Priority Date Filing Date
ES14190638.8T Active ES2632436T3 (es) 2009-03-10 2010-03-09 Aislamiento, identificación y caracterización de cepas con actividad probiótica a partir de heces de lactantes alimentados exclusivamente con leche materna
ES14190648.7T Active ES2636944T3 (es) 2009-03-10 2010-03-09 Aislamiento, identificación y caracterización de cepas con actividad probiótica a partir de heces de lactantes alimentados exclusivamente con leche materna
ES10750390.6T Active ES2532095T3 (es) 2009-03-10 2010-03-09 Aislamiento, identificacion y caracterizacion de cepas con actividad probiotica a partir de heces de lactantes alimentados exclusivamente con leche materna

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES14190638.8T Active ES2632436T3 (es) 2009-03-10 2010-03-09 Aislamiento, identificación y caracterización de cepas con actividad probiótica a partir de heces de lactantes alimentados exclusivamente con leche materna

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES10750390.6T Active ES2532095T3 (es) 2009-03-10 2010-03-09 Aislamiento, identificacion y caracterizacion de cepas con actividad probiotica a partir de heces de lactantes alimentados exclusivamente con leche materna

Country Status (8)

Country Link
US (3) US8637297B2 (es)
EP (3) EP2407532B1 (es)
CN (3) CN104232544B (es)
DK (3) DK2848682T3 (es)
ES (3) ES2632436T3 (es)
PL (3) PL2407532T3 (es)
RU (1) RU2551315C2 (es)
WO (2) WO2010103132A1 (es)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
NZ580006A (en) * 2007-03-28 2012-03-30 Alimentary Health Ltd Probiotic bifidobacterium strain 41387
CN103124559B (zh) 2010-08-04 2017-03-29 托马斯·朱利叶斯·波洛迪 用于粪便菌群植入的组合物及其制备和使用方法以及递送该组合物的装置
CA3119918A1 (en) 2011-03-09 2012-09-13 Regents Of The University Of Minnesota Compositions and methods for transplantation of colon microbiota
RU2453591C1 (ru) * 2011-04-21 2012-06-20 Общество с ограниченной ответственностью "Бифилюкс" Штамм lactobacillus rhamnosus, используемый для получения продукции, содержащей лактобактерии
KR101228035B1 (ko) * 2011-06-29 2013-01-30 주식회사 쎌바이오텍 신규한 유산균 및 이를 포함하는 당뇨병 예방 및 치료용 조성물
WO2013176774A1 (en) 2012-05-25 2013-11-28 Arizona Board Of Regents Microbiome markers and therapies for autism spectrum disorders
EP2917335B1 (en) * 2012-11-12 2018-04-04 Compagnie Gervais Danone Use of lactobacillus rhamnosus strain for reducing weight gain and/or insulin resistance
ES2468040B1 (es) * 2012-11-13 2014-12-26 Instituto Nacional De Investigación Y Tecnología Agraria Y Alimentaria (Inia) Microorganismo aislado de leche materna y de heces de un lactante, y su uso como probiótico
CN102960599A (zh) * 2012-11-19 2013-03-13 陕西科技大学 一种含益生元的双歧杆菌微胶囊的制备方法
ITRM20130174A1 (it) * 2013-03-22 2014-09-23 Eurospital S P A Ceppo di lactobacillus e suo uso come probiotico
CA3176938A1 (en) * 2013-08-09 2015-02-12 Ab-Biotics, S.A. Probiotic for infantile excessive crying
ITMI20131467A1 (it) 2013-09-06 2015-03-07 Sofar Spa Uso di una composizione comprendente microrganismi per aumentare la produzione intestinale di acido butirrico, di acido folico o di niacina e/o per diminuire la produzione intestinale di acido succinico
WO2015042683A1 (en) * 2013-09-26 2015-04-02 Hassan Firoozmand Biopolymer compositions comprising a plurality of treated single-celled microorganisms
JP6479768B2 (ja) * 2014-03-24 2019-03-06 大塚製薬株式会社 新規ラクトバチラス・パラカゼイ株
MA39710A (fr) 2014-04-23 2015-10-29 Sofar Spa Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin
RU2605626C2 (ru) * 2015-04-28 2016-12-27 Федеральное государственное бюджетное образовательное учреждение высшего образования "Кемеровский технологический институт пищевой промышленности (университет)" Способ получения бактериального препарата с пробиотической активностью
EP3294307A4 (en) 2015-05-14 2019-01-23 Crestovo Holdings Llc COMPOSITIONS FOR TRANSPLANTATION OF FECAL FLORA AND METHODS OF PREPARATION AND USE THEREOF, AND DEVICES FOR THEIR ADMINISTRATION
CA2986485A1 (en) 2015-05-22 2016-12-01 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
CN104894021B (zh) * 2015-06-03 2018-02-09 宜兰食品工业股份有限公司 一种副干酪乳杆菌及其应用
CN105176822B (zh) * 2015-10-23 2019-01-11 广州康泽医疗科技有限公司 一种人类肠道益生菌的优化分离方法
MA45288A (fr) 2016-06-08 2019-04-17 Sofar Spa Nouvelle utilisation médicale de probiotiques
US20170360848A1 (en) 2016-06-15 2017-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US10849936B2 (en) 2016-07-01 2020-12-01 Regents Of The University Of Minnesota Compositions and methods for C. difficile treatment
US20180036352A1 (en) 2016-08-03 2018-02-08 Crestovo Holdings Llc Methods for treating ulcerative colitis
US11026978B2 (en) 2016-10-11 2021-06-08 Finch Therapeutics Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
US10092601B2 (en) 2016-10-11 2018-10-09 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
WO2018071536A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating primary sclerosing cholangitis and related disorders
IT201600122724A1 (it) 2016-12-02 2018-06-02 Sofar Spa Exopolysaccharides and uses thereof
IT201600127498A1 (it) 2016-12-16 2018-06-16 Sofar Spa Probiotici per uso nella diverticolosi e malattia diverticolare
US11040073B2 (en) 2017-04-05 2021-06-22 Finch Therapeutics Holdings Llc Compositions and methods for treating diverticulitis and related disorders
US11433102B2 (en) 2017-04-05 2022-09-06 Finch Therapeutics Holdings Llc Compositions and methods for treating Parkinson's disease (PD) and related disorders
WO2018218159A1 (en) 2017-05-26 2018-11-29 Crestovo Holdings Llc Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same
EP3664823B1 (en) 2017-08-07 2024-06-05 Finch Therapeutics Holdings LLC Composition for use in preventing or treating an enterococcal blood stream infection
SG11202006428UA (en) * 2018-01-03 2020-08-28 Evolve Biosystems Inc Method for determining dysbiosis in the intestinal microbiome
JP7309212B2 (ja) * 2018-01-05 2023-07-18 ベネド バイオメディカル カンパニー リミテッド 新規な乳酸菌およびその応用
CN108315285A (zh) * 2018-05-08 2018-07-24 西藏高原之宝牦牛乳业股份有限公司 一种副干酪乳杆菌及其制备方法
WO2020006663A1 (zh) * 2018-07-02 2020-01-09 葡萄王生技股份有限公司 用于改善代谢症候群的新颖副干酪乳杆菌 gks6、其培养基、培养方法、用途、医药组合物及可食用组合物
US11166990B2 (en) 2018-07-13 2021-11-09 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
CN109134628A (zh) * 2018-09-26 2019-01-04 福建傲农生物科技集团股份有限公司 一种乳酸菌素plnE及其制备方法
CA3114423A1 (en) 2018-09-27 2020-04-02 Finch Therapeutics Holdings Llc Compositions and methods for treating epilepsy and related disorders
CN109536415B (zh) * 2018-12-26 2021-12-07 江西仁仁健康产业有限公司 一种鼠李糖乳杆菌及其应用
ES2940808T3 (es) 2019-01-16 2023-05-11 Nutricia Nv Preparado fermentado con oligosacáridos no digeribles para su uso en infecciones inducidas por rotavirus
US11865151B2 (en) * 2019-02-14 2024-01-09 Gutsybio Inc. Live biotherapeutics for the treatment of carbohydrate disorders
KR102139687B1 (ko) * 2019-05-03 2020-07-30 주식회사 메디오젠 가드네렐라 바기날리스 및 칸디다 알비칸스에 항균 효과를 갖는 질염 치료 또는 개선용 유산균 mg4288
JP7013419B2 (ja) * 2019-08-07 2022-02-15 日清食品ホールディングス株式会社 炎症性サイトカインの産生誘導活性は低いが抗炎症性サイトカインの産生誘導活性が高いビフィズス菌
IT201900020422A1 (it) * 2019-11-05 2021-05-05 Sofar Spa Composizioni comprendenti ceppi di batteri per uso per aumentare la biodisponibilità degli amminoacidi derivanti da proteine
US11751597B2 (en) 2019-11-05 2023-09-12 Alfasigma S.P.A. Compositions comprising bacterial strains for use in increasing the bioavailability of amino acids derived from proteins, and related food product methods and systems
EP3725167A1 (en) * 2019-11-11 2020-10-21 COREE S.r.l. Synergistic blends of probiotics expressing improved beneficial activity for human host favourably interacting with food, particularly baby food
WO2021242057A1 (ko) * 2020-05-28 2021-12-02 주식회사 바이오뱅크힐링 락토바실러스 속 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102296286B1 (ko) * 2020-06-16 2021-09-01 주식회사 바이오뱅크힐링 락토바실러스 람노서스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
CN113817622B (zh) * 2020-06-18 2023-05-26 青岛蔚蓝生物股份有限公司 一株具有减轻致癌物对人体细胞基因毒性作用的长双歧杆菌及其应用
CN111826312B (zh) * 2020-07-10 2022-03-25 江南大学 一株可缓解苯并芘暴露的鼠李糖乳杆菌及其应用
CN111733110B (zh) * 2020-07-17 2021-10-22 佛山市朗芯生物科技有限公司 副干酪乳杆菌及其在制备治疗溃疡性结肠炎药物中的应用
CN114317320B (zh) * 2020-08-24 2022-12-27 汤臣倍健股份有限公司 一种短双歧杆菌207-1及其应用
CN113265351B (zh) * 2021-05-11 2022-05-06 昆明理工大学 一株乳杆菌w8172及其应用
RU2766765C1 (ru) * 2021-05-25 2022-03-15 Федеральное государственное бюджетное учреждение "Детский научно-клинический центр инфекционных болезней Федерального медико-биологического агентства" Способ лечения функциональных заболеваний желудочно-кишечного тракта у детей
CN113322216B (zh) * 2021-07-30 2021-11-05 北京量化健康科技有限公司 一种副干酪乳杆菌b111h及其在代谢综合征中的应用
KR102562507B1 (ko) * 2021-12-08 2023-08-02 한국식품연구원 항염증 효과가 뛰어난 신규한 락토바실러스 파라카제이 아종 톨러란스 WiKim0148 및 이의 용도
CN114113023B (zh) * 2021-12-16 2024-04-26 郑州轻工业大学 基于单核增生李斯特菌来源的氮掺杂碳点的制备方法和应用
CN114292779A (zh) * 2021-12-22 2022-04-08 清远西周生物医药科技有限公司 一种副干酪乳杆菌冻干粉、其应用及制备方法
CN114381411B (zh) * 2022-03-23 2022-05-27 山东中科嘉亿生物工程有限公司 乳酸乳球菌jyll-60及其在制备提高免疫力的产品上的应用
CN115998777B (zh) * 2022-10-18 2023-11-17 汤臣倍健股份有限公司 副干酪乳杆菌207-27的用途
CN116731891B (zh) * 2022-12-07 2024-05-07 内蒙古科拓生物有限公司 一株短双歧杆菌b2798及其制备益生菌制剂的用途
CN116855413B (zh) * 2023-07-07 2024-02-09 镇江远森医药科技有限公司 利用鼠李糖乳杆菌YSs069制备调节人体微生态平衡的生物活性物质及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2124060T5 (es) * 1992-07-06 2002-12-16 Nestle Sa Bacteria lactica.
DE69841826D1 (de) * 1997-08-21 2010-09-23 New Zealand Dairy Board Immunitätsteigernde milchsäurebakterien
EP1034788A1 (en) * 1999-03-11 2000-09-13 Société des Produits Nestlé S.A. Lactic acid bacteria strains capable of preventing diarrhea
ES2238285T3 (es) * 1999-05-07 2005-09-01 Compagnie Gervais Danone Uso de bacterias acidolacticas en la preparacion de leches fermentadas para el tratamiento de niveles inmunitarios reducidos.
FI109602B (fi) * 2001-01-25 2002-09-13 Valio Oy Probioottiyhdistelmä
EP1384483A1 (en) * 2002-07-23 2004-01-28 Nestec S.A. Probiotics for treatment of irritable bowel disease (IBS) through improvement of gut neuromuscular function
EP2033529B1 (en) * 2003-10-24 2019-12-11 N.V. Nutricia Synbiotic composition for infants
ITMI20042189A1 (it) * 2004-11-16 2005-02-16 Anidral Srl Composizione a base di batteri probiotici e suo uso nella prevenzione e-o nel trattamento di patologie e-o infezioni respiratorie e nel miglioramento della funzionalita' intestinale
CN1259054C (zh) * 2004-12-27 2006-06-14 孙文基 龙胆苦苷在制备抑制乙型肝炎病毒药物中的应用
CA2604338A1 (en) * 2005-04-13 2006-10-19 Nestec S.A. Infant formula with probiotics
EP2269465A1 (en) * 2006-05-03 2011-01-05 Probiotical S.p.a. Compositions comprising Bifidobacterium adolescentis
WO2007140621A1 (en) * 2006-06-09 2007-12-13 Nutravital Inc. Probiotic compositions and uses thereof
US8066986B2 (en) * 2007-02-01 2011-11-29 Master Supplements, Inc. Formulations including digestive enzymes and polysorbate surfactants that enhance the colonization of administered probiotics microoganisms
EP1974743A1 (en) * 2007-03-28 2008-10-01 Nestec S.A. Probiotics to Improve Gut Microbiota
EP1997499A1 (en) * 2007-05-31 2008-12-03 Puleva Biotech, S.A. Mammalian milk microorganisms, compositions containing them and their use for the treatment of mastitis

Also Published As

Publication number Publication date
US8637297B2 (en) 2014-01-28
CN102421889B (zh) 2014-10-29
EP2407532A2 (en) 2012-01-18
DK2407532T3 (en) 2015-03-09
PL2407532T3 (pl) 2015-06-30
CN104232544B (zh) 2017-04-12
RU2551315C2 (ru) 2015-05-20
RU2011138363A (ru) 2013-04-20
US20120076829A1 (en) 2012-03-29
EP2407532A4 (en) 2013-04-10
EP2848681A1 (en) 2015-03-18
CN104232545A (zh) 2014-12-24
DK2848682T3 (en) 2017-09-11
US20130280789A1 (en) 2013-10-24
PL2848681T4 (pl) 2017-10-31
EP2848681B1 (en) 2017-04-12
CN104232545B (zh) 2017-11-21
ES2532095T3 (es) 2015-03-24
CN102421889A (zh) 2012-04-18
EP2848682B1 (en) 2017-05-31
EP2407532B1 (en) 2014-12-10
PL2848682T3 (pl) 2017-12-29
ES2632436T3 (es) 2017-09-13
WO2010103132A1 (es) 2010-09-16
DK2848681T3 (en) 2017-07-24
US20130280790A1 (en) 2013-10-24
WO2010103140A3 (es) 2010-11-04
WO2010103140A2 (es) 2010-09-16
PL2848681T3 (pl) 2017-10-31
EP2848682A1 (en) 2015-03-18
CN104232544A (zh) 2014-12-24

Similar Documents

Publication Publication Date Title
ES2636944T3 (es) Aislamiento, identificación y caracterización de cepas con actividad probiótica a partir de heces de lactantes alimentados exclusivamente con leche materna
ES2508566T3 (es) Cepas probióticas para su uso en mejorar el sistema nervioso entérico
Lahtinen et al. Prenatal probiotic administration can influence Bifidobacterium microbiota development in infants at high risk of allergy
Smelt et al. L. plantarum, L. salivarius, and L. lactis attenuate Th2 responses and increase Treg frequencies in healthy mice in a strain dependent manner
Cencič et al. Functional cell models of the gut and their applications in food microbiology—a review
ES2524432T3 (es) Bacterias del ácido láctico como cepas probióticas y composiciones que contienen las mismas
ES2616334T3 (es) Probióticos, IgA secretora e infección
ES2655697T3 (es) Mezcla de al menos 8 especies de bacterias de ácido láctico y/o bífidobacterias en la fabricación de masa madre
HRP20180053T1 (hr) Novi soj bakterije bifidobacterium animalis subsp. lactis cect 8145 i njegova upotreba u liječenju i/ili sprječavanju prekomjerne težine i pretilosti, te bolesti povezanih s njima
JP4942831B2 (ja) 抗アレルギー用組成物
DK1565547T3 (da) Probiotiske stammer, en fremgangsmåde til selektion deraf, præparater deraf samt anvendelse deraf
PE20001557A1 (es) Nueva cepa lactobacillus que previene diarrea causada por bacterias patogenas
Yanagibashi et al. Bacteroides induce higher IgA production than Lactobacillus by increasing activation-induced cytidine deaminase expression in B cells in murine Peyer’s patches
RU2011150195A (ru) Смесь для питания младенцев и маленьких детей, содержащая пробиотики для младенцев и маленьких детей
PE20190417A1 (es) Uso de probioticos en el tratamiento y/o la prevencion de la dermatitis atopica
Arboleya et al. In vitro evaluation of the impact of human background microbiota on the response to Bifidobacterium strains and fructo-oligosaccharides
US20110305679A1 (en) Blood-Cholesterol-Lowering Strain of Lactobacillus Delbrueckii
Bermudez-Brito et al. L. plantarum WCFS1 enhances Treg frequencies by activating DCs even in absence of sampling of bacteria in the Peyer Patches
Vinderola et al. Phage-resistant mutants of Lactobacillus delbrueckii may have functional properties that differ from those of parent strains
AR063809A1 (es) Nuevas cepas de bifidobacterias sensibles a la tetraciclina
Kabiri et al. Inhibitiory properties of cytoplasmic extract of Lactobacilli isolated from common carp intestine on human chronic myelocytic leukemia K562 cell line: an in vitro study.
AR071905A1 (es) Metodo para reducir borborigmos mediante la administracion de una bacteria bifidobacterium
ATE423196T1 (de) Antibiotikasensitive milchsäurebakterienstämme
Das Should probiotics be used in the treatment of acute childhood diarrhea?
Jeantet Innovative use of sweet whey to improve the viability of spray-dried probiotic bacteria